192,616 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Millrace Asset Group Inc.

Millrace Asset Group Inc. purchased a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 192,616 shares of the company’s stock, valued at approximately $1,568,000. Health Catalyst accounts for 1.6% of Millrace Asset Group Inc.’s portfolio, making the stock its 28th largest holding. Millrace Asset Group Inc. owned about 0.32% of Health Catalyst as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Quest Partners LLC acquired a new position in shares of Health Catalyst in the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC raised its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP boosted its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Health Catalyst during the third quarter worth $59,000. Finally, Perfromance Wealth Partners LLC bought a new stake in shares of Health Catalyst during the second quarter worth $64,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Trading Up 4.8 %

Shares of NASDAQ HCAT opened at $8.52 on Tuesday. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The stock has a market cap of $518.44 million, a price-to-earnings ratio of -6.31 and a beta of 1.32. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company’s fifty day moving average is $8.13 and its 200-day moving average is $7.28.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. Equities research analysts predict that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada increased their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Evercore ISI boosted their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Stephens upped their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

Insider Buying and Selling

In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the transaction, the chief operating officer now owns 134,899 shares of the company’s stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is owned by corporate insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.